Clinical characteristics of 51 patients after allogeneic HSCT
| Characteristic . | −cGVHD (N = 35) . | +cGVHD (N = 16) . | P . |
|---|---|---|---|
| No. of transplants (%) | |||
| 1 transplant | 31 (89) | 12 (75) | .24 |
| 2 transplants | 4 (11) | 4 (25) | |
| Median age, y (range) | 48 (21-70) | 49 (31-64) | .86 |
| Sex, no. (%) of females | 13 (37) | 8 (50) | .54 |
| Median time after transplant, mo (range) | 89 (36-396) | 64 (32-145) | .02 |
| Conditioning regimen (%) | |||
| Myeloblative | 20 (57) | 7 (56) | .55 |
| Nonmyeloblative | 15 (43) | 9 (44) | |
| Source of graft (%) | |||
| Peripheral blood | 29 (83) | 15 (94) | .41 |
| Bone marrow | 6 (17) | 1 (6) | |
| HLA matching (%) | |||
| Matched, unrelated | 14 (40) | 7 (44) | .85 |
| Matched, related | 16 (46) | 6 (38) | |
| Mismatched | 5 (14) | 3 (19) | |
| Immunosuppressive treatment (%) | |||
| None | 14 (40) | 2 (13) | .06 |
| Prednisone ≤ 50 mg (4-50 mg)/day | 8 (23) | 10 (63) | .01 |
| MMF | 2 (6) | 3 (19) | .31 |
| Tacrolimus | 4 (11) | 9 (56) | .001 |
| Rapamycin | 1 (3) | 1 (6) | .53 |
| ATG | 14 (40) | 9 (56) | .37 |
| Alemtuzumab | 1 (3) | 0 (0) | 1.00 |
| aGVHD grade 1-4 (%) | 16 (46) | 9 (56) | .56 |
| Disease (%) | |||
| AML/AML from MDS | 9 (26) | 9 (56) | .26 |
| ALL | 1 (3) | 0 (0) | |
| CML | 6 (17) | 0 (0) | |
| CLL | 2 (6) | 1 (6) | |
| MDS | 6 (17) | 2 (13) | |
| NHL | 6 (17) | 2 (13) | |
| MM | 1 (3) | 0 (0) | |
| AA | 1 (3) | 2 (13) | |
| Other | 3 (9) | 0 (0) |
| Characteristic . | −cGVHD (N = 35) . | +cGVHD (N = 16) . | P . |
|---|---|---|---|
| No. of transplants (%) | |||
| 1 transplant | 31 (89) | 12 (75) | .24 |
| 2 transplants | 4 (11) | 4 (25) | |
| Median age, y (range) | 48 (21-70) | 49 (31-64) | .86 |
| Sex, no. (%) of females | 13 (37) | 8 (50) | .54 |
| Median time after transplant, mo (range) | 89 (36-396) | 64 (32-145) | .02 |
| Conditioning regimen (%) | |||
| Myeloblative | 20 (57) | 7 (56) | .55 |
| Nonmyeloblative | 15 (43) | 9 (44) | |
| Source of graft (%) | |||
| Peripheral blood | 29 (83) | 15 (94) | .41 |
| Bone marrow | 6 (17) | 1 (6) | |
| HLA matching (%) | |||
| Matched, unrelated | 14 (40) | 7 (44) | .85 |
| Matched, related | 16 (46) | 6 (38) | |
| Mismatched | 5 (14) | 3 (19) | |
| Immunosuppressive treatment (%) | |||
| None | 14 (40) | 2 (13) | .06 |
| Prednisone ≤ 50 mg (4-50 mg)/day | 8 (23) | 10 (63) | .01 |
| MMF | 2 (6) | 3 (19) | .31 |
| Tacrolimus | 4 (11) | 9 (56) | .001 |
| Rapamycin | 1 (3) | 1 (6) | .53 |
| ATG | 14 (40) | 9 (56) | .37 |
| Alemtuzumab | 1 (3) | 0 (0) | 1.00 |
| aGVHD grade 1-4 (%) | 16 (46) | 9 (56) | .56 |
| Disease (%) | |||
| AML/AML from MDS | 9 (26) | 9 (56) | .26 |
| ALL | 1 (3) | 0 (0) | |
| CML | 6 (17) | 0 (0) | |
| CLL | 2 (6) | 1 (6) | |
| MDS | 6 (17) | 2 (13) | |
| NHL | 6 (17) | 2 (13) | |
| MM | 1 (3) | 0 (0) | |
| AA | 1 (3) | 2 (13) | |
| Other | 3 (9) | 0 (0) |
MMF indicates mycophenolate mofetil; ATG, antithymocyte globulin; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphoblastic leukemia; NHL, non-Hodgkin leukemia; MM, multiple myeloma; and AA, aplastic anemia.